Porro, M.G.

patient panobinostat 9- ac study pharmacokinetic phase model cancer sample ketoconazole inhibitor lactone 9- ac lactone analysis cyp 3a inhibitor concentration extension phase treatment point sample time points core phase plasma tumor strategy parameter table period prediction increase administration cyp 3a result correlation hypophosphatemia phosphate value cyp 3a inhibitors extension exposure jonge sparreboom pharmacokinetic parameters camptothecin interaction curve effect trial 9- aminocamptothecin drug administration regression fi rst dose verweij j coefficient event histone class level lymphoma ratio toxicity range phase i pharmacol safety deacetylase verweij correlation coefficients jonge mja enzyme limited-sampling aminocamptothecin drug –drug interactions chemother baseline evaluation cutaneous t-cell lymphoma difference 100 ll aliquot excretion loos wj